ACQUANDAS Sells Equity Stake to Synchron

Synchron has acquired an equity stake in ACQUANDAS, a technology provider specializing in high-precision components for various industries, including healthcare. Neither company disclosed the transaction’s financial terms.

“After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor. This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market,” AQUANDAS CEO/Founder Dr. Rodrigo Lima de Miranda stated.
 
As part of the deal, Synchron Founder/CEO Tom Oxley joins the ACQUANDAS Governance Council and Synchron Chief Technology Officer Riki Banerjee joins as Observer.
 
“This investment strengthens our technology innovation and supply chain for our product offerings, beginning with brain-computer interfaces,” Oxley said. 
 
ACQUANDAS has established an entirely new generation of shape-memory, flexible metallic components suitable for use as medical devices. Thei company’s capability to manufacture miniaturized structures, such as micro-patterned Nitinol thin films, combined with high structure resolution and geometrical complexity, excellent biocompatibility and improved mechanical properties, provides Synchron with a unique product offering in the implantable medical device industry.
 
Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and autonomy for individuals with motor impairment. Synchron is headquartered in New York City.